Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients

Current Opinion in HIV and AIDS

Volumn 10, Issue 5, 2015, Pages 337-347

  Del Bello, David ^a   Nagy, Fanny Ita ^a   Hand, Jonathan ^a   Khedemi, Rabea ^a   Lécluse Barth, Julien ^b   Dieterich, Douglas ^a   Piroth, Lionel ^b  

^a MOUNT SINAI HOSPITAL   (United States)

^b DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Direct antiviral agents; Hepatitis C virus; HIV

Indexed keywords

ANTIVIRUS AGENT; DACLASTASVIR; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR; ELBASVIR PLUS GRAZOPREVIR; GRAZOPREVIR; INTERFERON; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG; VELPATASVIR;

ANEMIA; CHRONIC HEPATITIS C; COMBINATION CHEMOTHERAPY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG INTERACTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INSOMNIA; MIXED INFECTION; NAUSEA; PRIORITY JOURNAL; PRURITUS; REVIEW; COMPLICATION; DRUG COMBINATION; HEPATITIS C, CHRONIC; PROCEDURES; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME;

EID: 84942933033     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000182     Document Type: Review

References (56)

1. WHO. Global Health Observatory (GHO) data: HIV/AIDS. http:// www.who.int/gho/hiv/en/
2. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-837.
3. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615-624.
4. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21:2209-2216.
5. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis Cvirus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
6. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs. standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-2848.
7. Sulkowski MS, Sherman K, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159:86-96.
8. Cotte L, Braun J, Lascoux-Combe C, et al. Telaprevir for HIV/hepatitis C viruscoinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. Clin Infect Dis 2014; 59:1768-1776.
9. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13:597-605.
10. Poizot-Martin I, Bellisant E, Colson P, et al. Boceprevir for previously treated HCV-HIV coinfected patients: The ANRS-HC27 BocepreVIH Trial. Conference on Retroviruses and Opportunistic Infections 2014; Boston, MA, USA abstract 659LB.
11. Dieterich D, Rockstroh J, Orkin C, et al. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Clin Infect Dis 2014; 59:1579-1587.
12. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312:353-361.
13. Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, nonrandomised, phase 3 study. Lancet 2015; 385:1098-1106.
14. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015; 313:1232-1239.
15. Naggie S, Cooper C, Saag M, et al. Ledipasvir/sofosbuvir for 12 weeks in patients coinfected With HCV and HIV-1. Conference on Retroviruses and Opportunistic Infections 2015; Seattle, USA. Abstract 152LB.
16. Wyles D, Ruane P, Sulkowski M, et al. Daclatasvir in combination with sofosbuvir for HIV/HCV coinfection: ALLY-2 study. Conference on Retroviruses and Opportunistic Infections 2015; Seattle, USA. Abstract 151LB.
17. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313:1223-1231.
18. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK- 8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385:1087-1097.
19. Rockstroh J, Katlama C, Lalezari J, et al. C-EDGE Co-infected: Phase 3 study of grazoprevir/elbasvir in patients with HCV/HIV. European Association for the Study of the Liver 2015; Vienna, Austria. Abstract P0687.
20. Basu P, Shah N, Brown Jr R. Simeprevir and sofosbuvir with modified doses of ribavirin therapy on telaprevir experienced co infected (with HIV) cirrhotics with chronic hepatitis C, a randomized open label clinical pilot study: STOP C. IEuropean Association for the Study of the Liver 2015; Vienna, Austria. Abstract P0819.
21. American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA) and the International Antiviral Society - USA (IAS-US) 2014 Recommendations for Testing, Managing, and Treating Hepatitis C. www.hcvguidelines.org
22. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63:199-236.
23. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonresponders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384:1756-1765.
24. Ingiliz P, Christensen S, Hueppe D, et al. German multicenter cohort on sofosbuvir based treatments in HCV mono- and HIV/HCV co-infected patients (GECOSO). European Association for the Study of the Liver 2015; Vienna, Austria. Abstract P0835.
25. Fontaine H, Lacombe K, Dhiver C, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HIV-HCV co-infection: interim analysis of a French multicenter compassionate use program. European Association for the Study of the Liver 2015; Vienna, Austria. Abstract LP23.
26. Sogni S, Gilbert C, Lacombe K, et al. Safety and efficacy of all-oral DAA regimens in HIV-HCV coinfected cirrhotic patients from the prospective ANRS CO13 - HEPAVIH cohort. European Association for the Study of the Liver 2015; Vienna, Austria. Abstract LP20.
27. Antonini T, Bedoya J, Teicher E, et al. Efficacy of sofosbuvir and daclatasvir in HIV/HCV co-infected patients with advanced fibrosis. In: European Association for the Study of the Liver 2015; Vienna, Austria. Abstract P0837.
28. Pianko S, Flamm SL, Shiffman ML, et al. High efficacy of treatment with sofosbuvir + GS-5816 for 12 weeks in treatment experienced patients with genotype 1 or 3 HCV infection. The American Association for the Study of Liver Diseases 2014; Boston, MA, USA abstract 197.
29. Tran TT, Morgan TR, Thuluvath PJ, et al. Safety and efficacy of treatment with sofosbuvir + GS-5816 - ribavirin for 8 or 12 weeks in treatment naive patients with genotype 1-6 HCV infection. European Association for the Study of the Liver 2014; Boston, MA, USA abstract 80.
30. Gane EJ, Hyland RH, An D, et al. Once daily sofosbuvir with GS-5816 for 8 weeks with or without ribavirin in patients with HCV genotype 3 without cirrhosis result in high rates of SVR 12: The ELECTRON2 Study. European Association for the Study of the Liver 2014; Boston, MA, USA abstract 79.
31. Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir with peginterferonribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 2015; 61:769-775.
32. Wong KA, Worth A, Martin R, et al. Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS- 5885. Antimicrob Agents Chemother 2013; 57:6333-6340.
33. Kohler JJ, Nettles JH, Amblard F, et al. Approaches to hepatitis C treatment and cure using NS5A inhibitors. Infect Drug Resist 2014; 7:41-56.
34. Gane EJ, Hyland RH, An D, et al. Sofosbuvir/ledpiasvir fied dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients with priori sofosbuvir treatment experience. J Hepatol 2015; 60:S3-S4.
35. Gane EJ, Hyland RH, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. American Association of Liver Diseases 2014; Boston, MA, USA abstract LB11.
36. Nelson DR, Cooper J, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61:1127-1135.
37. Kapoor R, Kohli A, Sidharthan S, et al. All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial. American Association for the Study of Liver Diseases 2014; Boston, MA. pp. Abstract 240.
38. Hezode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015; 385:2502-2509.
39. Ouwerkerk-Mahadevan S SV, Simion A, Peeters M, et al. The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with HIV antiretroviral agents in healthy volunteers. Infectious Disease Society Association (IDSA) Conference 2012; San Diego, California. Abstract 49.
40. Insert. Hp. http://www.gilead.com/-/media/Files/pdfs/medicines/liver-disease/ harvoni/harvoni-pi.pdf. Accessed 8 July 2015.
41. Karageorgopoulos DE, El-Sherif O, Bhagani S, Khoo SH. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/ hepatitis C virus coinfection. Curr Opin Infect Dis 2014; 27:36-45.
42. Insert. Sp. http://www.gilead.com/-/media/Files/pdfs/medicines/liver-disease/ harvoni/harvoni-pi.pdf. Accessed 8 July 2015.
43. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-1898.
44. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-1493.
45. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879- 1888.
46. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370:1993-2001.
47. Mangia A MP, Kwo P, et al. All oral fixed-dose combination ledipasvir/ sofosbuvir with or without ribavirin for 12 or 24 weeks in treatment-naive genotype 1 HCV-Infected patients: the phase 3 ION-1 study. In: EASL 49th Annual Meeting; 9-13 April 2014; London, abstract O167.
48. German P PP, West S, Han L, Sajwani K, Mathias A. Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy 19-21 May 2014; Washington, DC. Abstract O-06.
49. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT- 450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594-1603.
50. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370:1983-1992.
51. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973-1982.
52. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/rombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1604-1614.
53. Vikeira Pak [Package Insert]. North Chicago, IL: AbbVie Inc.
54. Kathri A WT, Wang H et al. 54th ICAAC edition Abstract V-483. 2013.
55. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370:211-221.
56. Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther 2013; 18:931-940.